29 May, 2017
Goldman Sachs upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Monday, November 23 to "Buy" rating. The stock exchanged hands 6.21 Million shares versus average trading capacity of 6.94 Million shares, yielding a market cap of $29.08 Billion.
Teva Pharmaceutical Industries Limited is a pharmaceutical company. Salem Investment Counselors Inc. increased its position in Teva Pharmaceutical Industries by 0.4% in the first quarter. The hedge fund run by Jeffrey Tannenbaum held 3.18M shares of the major pharmaceuticals company at the end of 2016Q4, valued at $115.20M, up from 2.83 million at the end of the previous reported quarter. Vantage Investment Partners LLC now owns 214,454 shares of the company's stock valued at $9,867,000 after buying an additional 10,654 shares during the period. AlphaOne also gave news articles about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. Finally, First City Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 0.4% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company's stock valued at $372,000 after buying an additional 1,004 shares during the period.
Jeffrey Tannenbaum increased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 12.44% based on its latest 2016Q4 regulatory filing with the SEC. MI ADV now owns 12,200 shares of the company's stock valued at $561,000 after buying an additional 2,000 shares in the last quarter. Institutional investors own 55.03% of the company's stock.
On the other hand the company has Relative Strength Index (RSI 14) of 30.36 along with Average True Range (ATR 14) of 0.83, Consequently Teva Pharmaceutical Industries Ltd (NYSE:TEVA)'s weekly and monthly volatility is 2.53%, 2.78% respectively. Fir Tree Inc bought 351,600 shares as the company's stock declined 15.11% while stock markets rallied. The firm's 50-day moving average price is $31.06 and its 200 day moving average price is $34.22.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) have shown a low EPS growth of -53.00% in the last 5 years and has earnings growth of -8.00% yoy. Gabelli reissued a "buy" rating on shares of Teva Pharmaceutical Industries in a research note on Monday, January 9th. The company reported $1.06 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $1.06.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)'s trailing twelve month revenues are $21.9 Billion, whereas its price to sales ratio for the same period is 1.31. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. During the same quarter a year ago, the company earned $1.20 earnings per share. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. Analysts forecast that Teva Pharmaceutical Industries will post $4.78 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 22nd. The ex-dividend date of this dividend is Thursday, June 1st. Teva Pharmaceutical Industries's dividend payout ratio (DPR) is presently 1,657.38%. If you are viewing this piece on another website, it was copied illegally and reposted in violation of USA and worldwide copyright and trademark laws.
In a research note sent to investors by Mizuho Securities on Friday, 26 May, the firm, Teva Pharmaceutical (NYSE:TEVA), had their PT lowered to $25.00. Credit Suisse initiated Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Wednesday, May 4.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)'s stock had its "market perform" rating reaffirmed by equities researchers at Wells Fargo & Co in a research note issued to investors on Saturday, April 29th. Maxim Group maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday, January 4 with "Buy" rating. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and fourteen have issued a buy rating to the stock.